U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H27ClN2O3S2
Molecular Weight 515.087
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of MK-571

SMILES

CN(C)C(=O)CCSC(SCCC(O)=O)C1=CC=CC(\C=C\C2=CC=C3C=CC(Cl)=CC3=N2)=C1

InChI

InChIKey=AXUZQJFHDNNPFG-UXBLZVDNSA-N
InChI=1S/C26H27ClN2O3S2/c1-29(2)24(30)12-14-33-26(34-15-13-25(31)32)20-5-3-4-18(16-20)6-10-22-11-8-19-7-9-21(27)17-23(19)28-22/h3-11,16-17,26H,12-15H2,1-2H3,(H,31,32)/b10-6+

HIDE SMILES / InChI

Molecular Formula C26H27ClN2O3S2
Molecular Weight 515.087
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 1
Optical Activity ( + / - )

MK-571 is a selective, orally active leukotriene D4/E4 (LTD4/E4) receptor antagonist patented by Merck Frosst Canada, Inc. for the treatment bronchoconstriction. In ex vivo models MK-571 competitively antagonizes contractions of guinea pig trachea and ileum induced by leukotriene (LT) D4 and LTE4 and contractions of human trachea induced by LTD4. MK-571 antagonizes bronchoconstriction induced in anesthetized guinea pigs by i.v. LTC4, LTD4, and LTE4 but do not block bronchoconstriction to arachidonic acid. In clinical trials, MK-571 is a potent antagonist of LTD4-induced bronchoconstriction in both normal volunteers and asthmatic patients.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9Y271
Gene ID: 10800.0
Gene Symbol: CYSLTR1
Target Organism: Homo sapiens (Human)
22.0 nM [EC50]
Target ID: P08183
Gene ID: 5243.0
Gene Symbol: ABCB1
Target Organism: Homo sapiens (Human)
PubMed

PubMed

TitleDatePubMed
Nrf2 Regulates the Sensitivity of Mouse Keratinocytes to Nitrogen Mustard via Multidrug Resistance-Associated Protein 1 (Mrp1).
2016-01
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.
2015-06
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).
2013-12
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013-11
Transcellular transport of aconitine across human intestinal Caco-2 cells.
2013-07
Arsenate accumulation and arsenate-induced glutathione export in astrocyte-rich primary cultures.
2013-06
Multidrug resistance protein 1 (ABCC1) confers resistance to arsenic compounds in human myeloid leukemic HL-60 cells.
2013-06
The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
2013-02-04
Multidrug resistance-associated protein 1 mediates 15-deoxy-Δ(12,14)-prostaglandin J2-induced expression of glutamate cysteine ligase expression via Nrf2 signaling in human breast cancer cells.
2011-08-15
Molecular characterization and functions of zebrafish ABCC2 in cellular efflux of heavy metals.
2011-05
Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes.
2011-04
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
2010-12
Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters.
2010-08-15
MRP transporters as membrane machinery in the bradykinin-inducible export of ATP.
2010-04
Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats.
2010-03
Multidrug resistance protein transporter and Ins(1,4,5)P₃-sensitive Ca²+-signaling involved in adenosine triphosphate export via Gq protein-coupled NK₂-receptor stimulation with neurokinin A.
2010
Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
2009-12
ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites.
2009-10-28
Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells.
2009-09
CYP1A1 induction and CYP3A4 inhibition by the fungicide imazalil in the human intestinal Caco-2 cells-comparison with other conazole pesticides.
2009-02-10
Cross-functioning between the extraneuronal monoamine transporter and multidrug resistance protein 1 in the uptake of adrenaline and export of 5-(glutathion-S-yl)adrenaline in rat cardiomyocytes.
2009-01
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
2008-10
Role of proline 1150 in functional interactions between the membrane spanning domains and nucleotide binding domains of the MRP1 (ABCC1) transporter.
2008-04-15
Cysteinyl leukotrienes mediate the enhancing effects of indomethacin and aspirin on eosinophil production in murine bone marrow cultures.
2008-02
Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species formation.
2007-10-19
Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.
2006-11-21
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
2006-01-01
Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5).
2005-09
Modulation of MRP1 protein transport by plant, and synthetically modified flavonoids.
2005-08-26
Inhibition of MRP1-mediated efflux in human erythrocytes by mono-anionic bile salts.
2005-08-17
Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes.
2005-08-15
Combined effects of GSTP1 and MRP1 in melanoma drug resistance.
2005-07-25
Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
2005-07
Mrp2/Abcc2 transport activity is stimulated by protein kinase Calpha in a baculo virus co-expression system.
2005-06-17
Expression and activity of multidrug resistance protein 1 in a murine thymoma cell line.
2005-04
Catfish egg lectin causes rapid activation of multidrug resistance 1 P-glycoprotein as a lipid translocase.
2005-03
MRP-1 expression levels determine strain-specific susceptibility to sodium arsenic-induced renal injury between C57BL/6 and BALB/c mice.
2005-02-15
Inhibitory activity of a green tea extract and some of its constituents on multidrug resistance-associated protein 2 functionality.
2005-02
Endogenous thiols and MRP transporters contribute to Hg2+ efflux in HgCl2-treated tubular MDCK cells.
2005-01-05
The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin.
2004-10-15
Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity.
2004-10
Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies.
2004-09-25
Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine.
2004-06
Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells.
2004-04-15
Inverse agonist activity of selected ligands of the cysteinyl-leukotriene receptor 1.
2004-04
Functional expression of the multidrug resistance protein 1 in microglia.
2003-10
Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug resistance-associated protein Mrp2 expressed in insect cells.
1998-06
Leukotriene D4-induced increases in cytosolic calcium in THP-1 cells: dependence on extracellular calcium and inhibition with selective leukotriene D4 receptor antagonists.
1994-06
Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects.
1993-12
Characterization of the leukotriene D4 receptor in dimethylsulphoxide-differentiated U937 cells: comparison with the leukotriene D4 receptor in human lung and guinea-pig lung.
1993-02-15
Patents

Patents

Sample Use Guides

1,500, 86, or 28 mg
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:14:33 GMT 2025
Edited
by admin
on Mon Mar 31 18:14:33 GMT 2025
Record UNII
76LB1G2X6V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MK-571
Common Name English
L 660711
Preferred Name English
L-660,711
Code English
PROPANOIC ACID, 3-(((3-(2-(7-CHLORO-2-QUINOLINYL)ETHENYL)PHENYL)((3-(DIMETHYLAMINO)-3-OXOPROPYL)THIO)METHYL)THIO)-, (E)-
Common Name English
MK 571
Code English
L-660711
Code English
(3-(3-(2-(7-CHLORO-2-QUINOLINYL)ETHENYL)PHENYL) ((3-DIMETHYL AMINO-3-OXO PROPYL)THIO)METHYL)THIO)PROPANOIC ACID
Common Name English
PROPANOIC ACID, 3-(((3-((1E)-2-(7-CHLORO-2-QUINOLINYL)ETHENYL)PHENYL)((3-(DIMETHYLAMINO)-3-OXOPROPYL)THIO)METHYL)THIO)-
Common Name English
Code System Code Type Description
FDA UNII
76LB1G2X6V
Created by admin on Mon Mar 31 18:14:33 GMT 2025 , Edited by admin on Mon Mar 31 18:14:33 GMT 2025
PRIMARY
EPA CompTox
DTXSID5048390
Created by admin on Mon Mar 31 18:14:33 GMT 2025 , Edited by admin on Mon Mar 31 18:14:33 GMT 2025
PRIMARY
PUBCHEM
5281888
Created by admin on Mon Mar 31 18:14:33 GMT 2025 , Edited by admin on Mon Mar 31 18:14:33 GMT 2025
PRIMARY
CAS
115104-28-4
Created by admin on Mon Mar 31 18:14:33 GMT 2025 , Edited by admin on Mon Mar 31 18:14:33 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
IC50
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR